

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
75660

MICROBIOLOGY REVIEW

8

OFFICE OF GENERIC DRUGS, HFD-640
Microbiology Review #1
August 14, 2000

A. 1. ANDA 75-660

APPLICANT Bedford Laboratories
270 Northfield Road,
Bedford, OH 44146

2. PRODUCT NAME: Milrinone Injection

3. DOSAGE FORM AND ROUTE OF ADMINISTRATION:
1 mg/mL, 10-mL/Vial and 20-mL/Vial

4. METHOD(S) OF STERILIZATION: ()

5. PHARMACOLOGICAL CATEGORY: Vasodilator.

B. 1. DATE OF INITIAL SUBMISSION: June 29, 1999
Subject of this Review (Received July 1, 1999)

2. DATE OF AMENDMENT: None

3. RELATED DOCUMENTS: None

4. ASSIGNED FOR REVIEW: August 7, 2000

C. REMARKS: The subject drug product is manufactured at Ben Venue Laboratories' manufacturing facilities in Bedford, OH and is filled in the Suites # 11, 13, 111 and 112. The subject drug product, filled in glass vials and fitted with rubber stoppers is () by ()

D. CONCLUSIONS: The submission is not recommended for approval on the basis of sterility assurance. Specific comments are provided in "E. Review Notes" and "Microbiology Comments to be Provided to the Applicant" found at the end of this review. The deficiencies represent a Fax amendment.

22/14/00

Nrapendra Nath, Ph. D.

CC: Original ANDA
Duplicate ANDA
Division Copy
Field Copy
Drafted by N. Nath, HFD 600; V:\microrev\75660.doc
Initialed by A. High

(CBH)
8/17/00

Redacted 9

pages of trade

secret and/or

confidential

commercial

information

Micro Review #1

Microbiology Comments to be Provided to the Applicant

ANDA: 75-660

APPLICANT: Bedford Laboratories

DRUG PRODUCT: Milrinone Injection,
1 mg/mL, 10-mL/Vial and 20-mL/Vial

A. Microbiology Deficiencies:

1. It is recognized that the subject drug product is (subject drug product) however, the formulation of the subject drug product includes dextrose and lactic acid. The bulk solution of the subject drug product held at room temperature could support microbial growth. Please define your policy regarding the 'holding time' and the conditions under which the Bulk Product Solution may be held prior to its filtration.

Please clearly identify your amendment to this facsimile as RESPONSE TO MICROBIOLOGY DEFICIENCIES. The RESPONSE TO MICROBIOLOGY DEFICIENCIES should also be noted in your cover page/letter.

Sincerely yours,

/S/

Mary Hanning, M.D., Ph.D.
Associate Director of Medical Affairs
Office of Generic Drugs
Center for Drug Evaluation and Research

OFFICE OF GENERIC DRUGS, HFD-640

Microbiology Review #2

June 25, 2001

A. 1. ANDA 75-660

APPLICANT Bedford Laboratories
270 Northfield Road,
Bedford, OH 44146

2. PRODUCT NAME: Milrinone Injection

3. DOSAGE FORM AND ROUTE OF ADMINISTRATION:

1 mg/mL, 10-mL/Vial and 20-mL/Vial *and 50-mL/Vial*

4. METHOD(S) OF STERILIZATION: (

5. PHARMACOLOGICAL CATEGORY: Vasodilator.

B. 1. DATE OF INITIAL SUBMISSION: June 29, 1999

2. DATE OF AMENDMENT: September 12, 2000

Subject of this Review (Received September 14, 2000)

3. RELATED DOCUMENTS: None

4. ASSIGNED FOR REVIEW: June 25, 2001

C. REMARKS: The subject amendment provides for the response to microbiology deficiencies in the correspondence dated August 23, 2000. The applicant has submitted a single dose 50-mL vial as a gratuitous amendment; microbiology review of the amendment is included.

D. CONCLUSIONS: The submission is recommended for approval on the basis of sterility assurance. Specific comments are provided in "E." Review Notes".

/S/

Nrapendra Nath, Ph. D.

6/26/01
CSW 6/26/01

CC: Original ANDA
Duplicate ANDA
Division Copy
Field Copy

Drafted by N. Nath, HFD 600; V:\microrev\75660a1.doc
Initialed by A. High

Redacted 2

pages of trade

secret and/or

confidential

commercial

information

Micro Review # 2